Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 209

1.

Patient-Reported Barriers are Associated with Lower HCC Surveillance Rates in Patients with Cirrhosis.

Farvardin S, Patel J, Khambaty M, Yerokun OA, Mok H, Tiro JA, Yopp AC, Parikh ND, Marrero JA, Singal AG.

Hepatology. 2016 Aug 17. doi: 10.1002/hep.28770. [Epub ahead of print]

PMID:
27531684
2.

Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: the GIDEON study.

Marrero JA, Kudo M, Venook AP, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JH, de Guevara LL, Papandreou C, Takayama T, Sanyal AJ, Yoon SK, Nakajima K, Lehr R, Heldner S, Lencioni R.

J Hepatol. 2016 Jul 25. pii: S0168-8278(16)30346-4. doi: 10.1016/j.jhep.2016.07.020. [Epub ahead of print]

PMID:
27469901
3.

Hospital Volume and Survival After Hepatocellular Carcinoma Diagnosis.

Mokdad AA, Zhu H, Marrero JA, Mansour JC, Singal AG, Yopp AC.

Am J Gastroenterol. 2016 Jul;111(7):967-75. doi: 10.1038/ajg.2016.181. Epub 2016 May 10.

PMID:
27166130
4.

Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study.

Kudo M, Lencioni R, Marrero JA, Venook AP, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, Ladrón de Guevara L, Papandreou C, Sanyal AJ, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Ye SL.

Liver Int. 2016 Aug;36(8):1196-205. doi: 10.1111/liv.13096. Epub 2016 Apr 1.

PMID:
26901163
5.

TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON.

Geschwind JF, Kudo M, Marrero JA, Venook AP, Chen XP, Bronowicki JP, Dagher L, Furuse J, Ladrón de Guevara L, Papandreou C, Sanyal AJ, Takayama T, Ye SL, Yoon SK, Nakajima K, Lehr R, Heldner S, Lencioni R.

Radiology. 2016 May;279(2):630-40. doi: 10.1148/radiol.2015150667. Epub 2016 Jan 8.

PMID:
26744927
6.

The Doylestown Algorithm: A Test to Improve the Performance of AFP in the Detection of Hepatocellular Carcinoma.

Wang M, Devarajan K, Singal AG, Marrero JA, Dai J, Feng Z, Rinaudo JA, Srivastava S, Evans A, Hann HW, Lai Y, Yang H, Block TM, Mehta A.

Cancer Prev Res (Phila). 2016 Feb;9(2):172-9. doi: 10.1158/1940-6207.CAPR-15-0186. Epub 2015 Dec 28.

PMID:
26712941
7.

ESI-LC-MS Method for Haptoglobin Fucosylation Analysis in Hepatocellular Carcinoma and Liver Cirrhosis.

Zhang Y, Zhu J, Yin H, Marrero J, Zhang XX, Lubman DM.

J Proteome Res. 2015 Dec 4;14(12):5388-95. doi: 10.1021/acs.jproteome.5b00792. Epub 2015 Nov 3.

PMID:
26503433
8.

Mass Spectrometric N-Glycan Analysis of Haptoglobin from Patient Serum Samples Using a 96-Well Plate Format.

Zhu J, Wu J, Yin H, Marrero J, Lubman DM.

J Proteome Res. 2015 Nov 6;14(11):4932-9. doi: 10.1021/acs.jproteome.5b00662. Epub 2015 Oct 13.

PMID:
26448449
9.

Mass-Selected Site-Specific Core-Fucosylation of Serum Proteins in Hepatocellular Carcinoma.

Yin H, Tan Z, Wu J, Zhu J, Shedden KA, Marrero J, Lubman DM.

J Proteome Res. 2015 Nov 6;14(11):4876-84. doi: 10.1021/acs.jproteome.5b00718. Epub 2015 Oct 2.

PMID:
26403951
10.

Two enzymes with redundant fructose bisphosphatase activity sustain gluconeogenesis and virulence in Mycobacterium tuberculosis.

Ganapathy U, Marrero J, Calhoun S, Eoh H, de Carvalho LP, Rhee K, Ehrt S.

Nat Commun. 2015 Aug 10;6:7912. doi: 10.1038/ncomms8912.

11.

Coumarin heterocyclic derivatives: chemical synthesis and biological activity.

Medina FG, Marrero JG, Macías-Alonso M, González MC, Córdova-Guerrero I, Teissier García AG, Osegueda-Robles S.

Nat Prod Rep. 2015 Sep 23;32(10):1472-507. doi: 10.1039/c4np00162a. Review.

PMID:
26151411
12.

Integrating Source Apportionment Tracers into a Bottom-up Inventory of Methane Emissions in the Barnett Shale Hydraulic Fracturing Region.

Townsend-Small A, Marrero JE, Lyon DR, Simpson IJ, Meinardi S, Blake DR.

Environ Sci Technol. 2015 Jul 7;49(13):8175-82. doi: 10.1021/acs.est.5b00057.

PMID:
26148556
13.

Hepatocellular carcinoma tumor board: making sense of the technologies.

Abou-Alfa GK, Marrero J, Renz J, Lencioni R.

Am Soc Clin Oncol Educ Book. 2015:e213-20. doi: 10.14694/EdBook_AM.2015.35.e213. Review.

14.

Recovery of Nickel and Cobalt from Laterite Tailings by Reductive Dissolution under Aerobic Conditions Using Acidithiobacillus Species.

Marrero J, Coto O, Goldmann S, Graupner T, Schippers A.

Environ Sci Technol. 2015 Jun 2;49(11):6674-82. doi: 10.1021/acs.est.5b00944. Epub 2015 May 14.

PMID:
25923144
15.

Response to Zanini et al.

Ahn J, Marrero J, Reddy RK.

Am J Gastroenterol. 2015 Apr;110(4):600. doi: 10.1038/ajg.2015.60. No abstract available.

PMID:
25853203
16.

ACG clinical guideline: the diagnosis and management of focal liver lesions.

Marrero JA, Ahn J, Rajender Reddy K; Americal College of Gastroenterology.

Am J Gastroenterol. 2014 Sep;109(9):1328-47; quiz 1348. doi: 10.1038/ajg.2014.213. Epub 2014 Aug 19.

PMID:
25135008
17.

Partnering with Cuba: weather extremes.

Marrero JC, Miller MM, Mattioli G, Feaux K, Anthes R, Braun J, Wang G, Robock A.

Science. 2014 Jul 18;345(6194):278. doi: 10.1126/science.345.6194.278-a. Epub 2014 Jul 17. No abstract available.

PMID:
25035480
18.

Emerging trends in hepatocellular carcinoma: focus on diagnosis and therapeutics.

Flores A, Marrero JA.

Clin Med Insights Oncol. 2014 May 19;8:71-6. doi: 10.4137/CMO.S9926. eCollection 2014. Review.

19.

Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma.

Gish RG, Finn RS, Marrero JA.

Gastroenterol Hepatol (N Y). 2013 Apr;9(4 Suppl 2):1-24.

20.

Inactivation of fructose-1,6-bisphosphate aldolase prevents optimal co-catabolism of glycolytic and gluconeogenic carbon substrates in Mycobacterium tuberculosis.

Puckett S, Trujillo C, Eoh H, Marrero J, Spencer J, Jackson M, Schnappinger D, Rhee K, Ehrt S.

PLoS Pathog. 2014 May 22;10(5):e1004144. doi: 10.1371/journal.ppat.1004144. eCollection 2014 May.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk